Abstract:Protein tyrosine phosphatases (PTPs) are the group of enzymes that control both cellular activity and the dephosphorylation of tyrosine (Tyr)-phosphorylated proteins. Dysregulation of PTP1B has contributed to numerous diseases including Diabetes Mellitus, Alzheimer's disease, and obesity rendering PTP1B as a legitimate target for therapeutic applications. It is highly challenging to target this enzyme because of its highly conserved and positively charged active-site pocket motivating researchers to find novel lead compounds against it. The present work makes use of an integrated approach combining ligand-based and structure-based virtual screening to find hit compounds targeting PTP1B. Initially, pharmacophore modeling was performed to find common features like two hydrogen bond acceptors, an aromatic ring and one hydrogen bond donor from the potent PTP1B inhibitors. The dataset of compounds matching with the common pharmacophoric features was filtered to remove Pan-Assay Interference substructure and to match the Lipinski criteria. Then, compounds were further prioritized using molecular docking and top fifty compounds with good binding affinity were selected for absorption, distribution, metabolism, and excretion (ADME) predictions. The top five compounds with high solubility, absorption and permeability holding score of − 10 to − 9.3 kcal/mol along with Ertiprotafib were submitted to all-atom molecular dynamic (MD) studies. The MD studies and binding free energy calculations showed that compound M4, M5 and M8 were having better binding affinity for PTP1B enzyme with ∆G total score of − 24.25, − 31.47 and − 33.81 kcal/mol respectively than other compounds indicating that compound M8 could be a suitable lead compound as PTP1B inhibitor.

Metal-Based Inhibitors of Protein Tyrosine Phosphatases

Protein tyrosine phosphatase inhibition by metals and metal complexes.

Exploration of Zinc(II) Complexes As Potent Inhibitors Against Protein Tyrosine Phosphatase 1B

Targeting PTPs with small molecule inhibitors in cancer treatment

Recent Advances in the Development of Allosteric Protein Tyrosine Phosphatase Inhibitors for Drug Discovery.

Structure-Based Discovery of Small Molecule Inhibitors Targeted to Protein Tyrosine Phosphatase 1B

Recent Advance on PTP1B Inhibitors and Their Biomedical Applications.

Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases

Recent Progress in Protein Tyrosine Phosphatase 1B Inhibitors

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Druggable targets of protein tyrosine phosphatase Family, viz. PTP1B, SHP2, Cdc25, and LMW-PTP: Current scenario on medicinal Attributes, and SAR insights

Advance in regulatory mechanism research of protein tyrosine phosphatases

Protein tyrosine phosphatase 1B in metabolic diseases and drug development

Protein tyrosine phosphatase 1B in metabolic and cardiovascular diseases: from mechanisms to therapeutics

Progress in protein tyrosine phosphates(PTPs) related to insulin signaling pathway

Structure-activity Relationship of Protein Tyrosine Phosphatase 1B Inhibitors

Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B.

Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.

Integrated use of ligand and structure-based virtual screening, molecular dynamics, free energy calculation and ADME prediction for the identification of potential PTP1B inhibitors

Molecular Dynamics Studies on the Interactions of Ptp1b with Inhibitors: from the First Phosphate-Binding Site to the Second One

Recent progress in research on protein tyrosine phosphatase 1B and its inhibitors